US OptionsDetailed Quotes

INMB250516C7500

Watchlist

0.10
-0.18-64.29%

15min DelayClose May 9 15:57 ET

0.10High0.10Low

INmune Bio Stock Discussion

Teddy123

Apr 16 19:07

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

$INmune Bio (INMB.US)$
Patent Win: INmune Bio's Revolutionary Cell Therapy Secures 20+ Years Protection

Trytosaveabit

Apr 16 19:04

update

$INmune Bio (INMB.US)$ INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE

Teddy123

Apr 14 20:23

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

$INmune Bio (INMB.US)$
INmune Bio's Game-Changing Partnership Accelerates CORDStrom Production for 4,000 RDEB Patients

Jaguar8

Apr 14 20:09

NEWS

$INmune Bio (INMB.US)$
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
Monday, 14th April at 8:00 am
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial...

Jaguar8

Apr 7 05:14

🔵Watchlist, APRIL 7,2025, Monday. NFA -DrJag8

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...

Trytosaveabit

Apr 2 06:13

Note the dates in last paragraph

$INmune Bio (INMB.US)$ INmune Bio, Inc. (INMB), a clinical-stage immunology company, Tuesday announced that it is presenting findings from its MINDFuL Phase II trial at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2025 in Vienna.
The trial focuses on early Alzheimer's disease (AD) patients with confirmed biomarkers of inflammation.
The study enrolled 208 patients, categorized as mild cognitive impairment (MCI, 44%) or mild AD (mAD,...

Teddy123

Apr 1 19:08

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

$INmune Bio (INMB.US)$
Promising Patient Profile Emerges in Major Alzheimer's Drug Trial: 69% Carry Key Risk Gene

Teddy123

Mar 28 12:39

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

$INmune Bio (INMB.US)$
INmune Bio's Triple Threat: Alzheimer's Trial Fully Enrolled, FDA Designations Secured

Trytosaveabit

Mar 28 05:03

Not hateful! But BUT pay attention to dates! Possible catalyst events!

$INmune Bio (INMB.US)$ Corporate:
● Completed repayment of outstanding Silicon Valley Bank term loan in December.
● Executed securities purchase agreements with new and existing institutional investors and certain directors, officers and employees of the Company for total gross proceeds of approximately $27.5 million. As part of the offerings, the company issued approximately 3.9 million warrants to purchase common stock. The...

Jaguar8

Feb 10 20:03

NEWS

$INmune Bio (INMB.US)$
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Monday, 10th February at 7:00 am
• The Company reports results of a double-blinded, randomized, placebo-controlled study, known as "MissionEB," investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a favorable benefit-risk profile in support of the intended applications...

No comment yet